Почетна › Рак дојке › Mičigen › Detroit
Kliničke studije za Рак дојке u gradu Detroit, MI
34 studija za Рак дојке traži učesnike na lokacijama u gradu Detroit i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Тражи се учесникФаза 3
- Henry Ford Hospital, Detroit
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Тражи се учесникФаза 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Тражи се учесникФаза 1/2
- Research Facility, Detroit
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Тражи се учесникФаза 1/2
- Karmanos Cancer Institute, Detroit
- Brigitte Harris Cancer Pavilion BHCP, Detroit
The Vanguard Study: Testing a New Way to Screen for Cancer
Тражи се учесникЗдраве особе су добродошле
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Тражи се учесник
- Karmanos Cancer Center - Wayne State University, Detroit
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Тражи се учесникФаза 3
- Henry Ford Health System, Detroit
E-Mindfulness Approaches for Living After Breast Cancer
Тражи се учесникФаза 3
- Henry Ford Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Тражи се учесникФаза 1/2
- Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Тражи се учесникФаза 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Тражи се учесникФаза 1
- Barbara Ann Karmanos Cancer Institute, Detroit
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Тражи се учесникФаза 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Тражи се учесникФаза 3
- Karmanos Cancer Center, Detroit
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Тражи се учесникФаза 2
- Henry Ford Hospital, Detroit
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Wayne State University - Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Тражи се учесникФаза 3
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Тражи се учесникФаза 1
- Karmanos Cancer Institiute, Detroit
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Тражи се учесникФаза 3
- Henry Ford Health ( Site 0002), Detroit
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Тражи се учесникФаза 1/2
- Henry Ford Hospital, Detroit
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Тражи се учесникФаза 3
- Henry Ford Health System, Detroit
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Тражи се учесникФаза 3
- Research Site, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Тражи се учесникФаза 1
- Henry Ford Cancer Institute, Detroit
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
Тражи се учесник
- Karmanos Cancer Institute, Detroit
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Тражи се учесникФаза 3
- Wayne State University/Karmanos Cancer Institute, Detroit
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Тражи се учесникФаза 2/3
- Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
Тражи се учесникЗдраве особе су добродошле
- Henry Ford Health, Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Тражи се учесникФаза 1/2
- Henry Ford Health Hospital, Detroit
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Тражи се учесникФаза 1/2
- Henry Ford Hospital, Detroit
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Тражи се учесникФаза 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of the TheraBionic P1 Device in Breast Cancer
Тражи се учесник
- Karmanos Cancer Institute, Detroit
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Тражи се учесникФаза 1/2
- Henry Ford Health System, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Тражи се учесникФаза 1/2
- Karmanos Cancer Institute, Detroit
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
Тражи се учесник
- Karmanos Cancer Institute, Detroit
Studije za Рак дојке u drugim gradovima
- New York City, NY144 студија
- Houston, TX126 студија
- Boston, MA110 студија
- Nashville, TN78 студија
- Los Angeles, CA73 студија
- Edison, NJ70 студија
- Queens, NY67 студија
- Durham, NC63 студија
- St. Louis, MO63 студија
- Chicago, IL59 студија
- Dallas, TX54 студија
- Philadelphia, PA51 студија
Ostale studije u gradu Detroit
- Немалоклетни карцином плућа40 студија
- Рак јајника28 студија
- Рак (све врсте)27 студија
- Колоректални карцином25 студија
- Рак простате23 студија
- Карцином ендометријума23 студија
- Метастатски карцином22 студија
- Рак плућа19 студија
- Многи мијелом19 студија
- Плоскоклеточни карцином главе и врата16 студија
- Рак желуца15 студија
- Затајење срца14 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.